Two phase, open-label, sequential, ascending dose study of the tolerability, safety, and pharmacokinetics of CRA-024781 [PCI 24781] in cancer patients

Trial Profile

Two phase, open-label, sequential, ascending dose study of the tolerability, safety, and pharmacokinetics of CRA-024781 [PCI 24781] in cancer patients

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Abexinostat (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 20 Aug 2008 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
    • 13 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.
    • 15 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top